0.00
price down icon100.00%   -4.97
 
loading
前日終値:
$4.97
開ける:
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額:
$48.77M
収益:
$21.73M
当期純損益:
$-91.17M
株価収益率:
0.00
EPS:
-0.74
ネットキャッシュフロー:
$-286.43M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
Value
$0.00
$0.00
1週間の範囲:
Value
$0.00
$0.00
52週間の値動き範囲:
Value
$0.00
$28.60

Bluebird Bio Inc Stock (BLUE) Company Profile

Name
名前
Bluebird Bio Inc
Name
セクター
Healthcare (1174)
Name
電話
339-499-9300
Name
住所
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Name
職員
375
Name
Twitter
@bluebirdbio
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
BLUE's Discussions on Twitter

BLUE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BLUE
Bluebird Bio Inc
0.00 48.77M 21.73M -91.17M -286.43M -0.74
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-24 アップグレード JP Morgan Underweight → Neutral
2024-11-15 ダウングレード BofA Securities Buy → Neutral
2024-11-15 ダウングレード JP Morgan Neutral → Underweight
2024-08-15 ダウングレード JP Morgan Overweight → Neutral
2023-12-11 ダウングレード HSBC Securities Hold → Reduce
2023-12-08 アップグレード Morgan Stanley Underweight → Equal-Weight
2023-10-17 開始されました Cantor Fitzgerald Neutral
2023-09-06 開始されました HSBC Securities Buy
2023-07-19 アップグレード BofA Securities Neutral → Buy
2023-06-01 アップグレード Barclays Equal Weight → Overweight
2023-04-28 開始されました JP Morgan Overweight
2023-03-07 開始されました Robert W. Baird Outperform
2022-08-05 アップグレード Barclays Underweight → Equal Weight
2022-08-02 アップグレード Raymond James Mkt Perform → Outperform
2022-04-06 ダウングレード Cowen Outperform → Market Perform
2022-03-07 ダウングレード Barclays Equal Weight → Underweight
2021-11-08 繰り返されました Barclays Equal Weight
2021-11-08 繰り返されました Canaccord Genuity Hold
2021-11-08 ダウングレード Goldman Neutral → Sell
2021-11-08 ダウングレード Morgan Stanley Equal-Weight → Underweight
2021-11-08 繰り返されました RBC Capital Mkts Sector Perform
2021-11-08 繰り返されました Wedbush Neutral
2021-11-08 繰り返されました Wells Fargo Equal Weight
2021-08-10 ダウングレード Canaccord Genuity Buy → Hold
2021-08-10 ダウングレード Goldman Buy → Neutral
2021-08-10 ダウングレード Wells Fargo Overweight → Equal Weight
2021-08-10 再開されました William Blair Mkt Perform
2021-08-09 ダウングレード SVB Leerink Outperform → Mkt Perform
2021-07-01 ダウングレード Berenberg Buy → Hold
2021-03-10 アップグレード Mizuho Neutral → Buy
2021-02-17 ダウングレード JP Morgan Overweight → Neutral
2021-02-16 ダウングレード BofA Securities Buy → Neutral
2021-02-16 ダウングレード Wedbush Outperform → Neutral
2021-02-16 ダウングレード William Blair Outperform → Mkt Perform
2020-12-09 ダウングレード Maxim Group Buy → Hold
2020-11-11 開始されました Berenberg Buy
2020-11-05 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-11-05 ダウングレード Barclays Overweight → Equal Weight
2020-11-05 ダウングレード Stifel Buy → Hold
2020-11-02 アップグレード William Blair Mkt Perform → Outperform
2020-10-20 開始されました Mizuho Buy
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-03-27 アップグレード Stifel Hold → Buy
2020-02-19 ダウングレード Raymond James Outperform → Mkt Perform
2020-02-03 再開されました BofA/Merrill Buy
2020-02-03 アップグレード Evercore ISI In-line → Outperform
2019-12-13 アップグレード Oppenheimer Perform → Outperform
2019-11-26 アップグレード SVB Leerink Mkt Perform → Outperform
2019-11-19 ダウングレード Evercore ISI Outperform → In-line
2019-11-04 アップグレード Wedbush Neutral → Outperform
2019-10-01 開始されました Stifel Hold
2019-08-12 ダウングレード William Blair Outperform → Mkt Perform
2019-06-18 アップグレード Maxim Group Hold → Buy
すべてを表示

Bluebird Bio Inc (BLUE) 最新ニュース

pulisher
Jun 18, 2025

Inside the Future of the Gene Therapy for SCID Market: Forecasts, - openPR.com

Jun 18, 2025
pulisher
Jun 12, 2025

Carlyle and SK Capital Complete Acquisition of bluebird bio - orrick.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bluebird bio Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

Bank of America Corp DE Sells 1,358,195 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

As Gene Therapy Endures ‘Cold Winter,’ FDA Leaders Promise Support - BioSpace

Jun 11, 2025
pulisher
Jun 11, 2025

Adrenoleukodystrophy Treatment Market Overview | HSCT, Gene - openPR.com

Jun 11, 2025
pulisher
Jun 07, 2025

Nuveen Asset Management LLC Decreases Stock Position in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

BNP Paribas Financial Markets Decreases Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

bluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK Capital - MSN

Jun 05, 2025
pulisher
Jun 04, 2025

Beta-Thalassemia (B-thal) Market Set to Witness - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

Sickle Cell Treatment Market 2025 | Advances, Drugs, Therapies & - openPR.com

Jun 04, 2025
pulisher
Jun 03, 2025

bluebird bio acquired to scale gene therapy access By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $47,000 Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Deutsche Bank AG Cuts Stake in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Carlyle, SK Capital close deal for bluebird bio, injecting capital for commercial expansion - The Business Journals

Jun 02, 2025
pulisher
Jun 02, 2025

Bluebird Bio (BLUE) Acquired by Carlyle and SK Capital Partners | BLUE Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Carlyle, SK Capital Partners Close Bluebird Bio Acquisition - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

bluebird bio acquired to scale gene therapy access - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital - Business Wire

Jun 02, 2025
pulisher
May 31, 2025

Carlyle, SK Capital Partners disclose expected closing date of bluebird bio deal - MSN

May 31, 2025
pulisher
May 31, 2025

Carlyle and SK Capital to acquire bluebird bio By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 31, 2025

Northern Trust Corp Reduces Holdings in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

May 31, 2025
pulisher
May 30, 2025

Bluebird Bio (BLUE) Acquisition Nears Completion - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Carlyle, SK Capital, Beacon Set To Close Bluebird Bio Acquisition - Nasdaq

May 30, 2025
pulisher
May 30, 2025

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Carlyle and SK Capital to acquire bluebird bio - Investing.com India

May 30, 2025
pulisher
May 30, 2025

Carlyle-Led Group Closes Tender Offer for Bluebird Bio - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer | BLUE Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Carlyle's $5 Per Share Bluebird Bio Takeover Set for June 2 Close After Successful Tender - Stock Titan

May 30, 2025
pulisher
May 29, 2025

Bluebird Bio's Acquisition Deal Offers Shareholders New Cash Option - Finimize

May 29, 2025
pulisher
May 27, 2025

Bluebird Bio Beats Investor Suit Over FDA Cancer Warning - Law360

May 27, 2025
pulisher
May 27, 2025

Bluebird Bio’s SWOT analysis: biotech firm’s stock faces merger crossroads By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Bluebird Bio’s SWOT analysis: biotech firm’s stock faces merger crossroads - Investing.com

May 27, 2025
pulisher
May 27, 2025

Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's

May 27, 2025
pulisher
May 27, 2025

bluebird bio Reminds Stockholders to Act Now to Tender Shares fo - GuruFocus

May 27, 2025
pulisher
May 27, 2025

bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital - BioSpace

May 27, 2025
pulisher
May 27, 2025

Bluebird Beats Investor Lawsuit Over FDA Black Box Warning (1) - Bloomberg Law News

May 27, 2025
pulisher
May 27, 2025

bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus

May 27, 2025
pulisher
May 25, 2025

High Noon For bluebird (NASDAQ:BLUE) - Seeking Alpha

May 25, 2025
pulisher
May 20, 2025

PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stoc - GuruFocus

May 20, 2025
pulisher
May 20, 2025

PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) Price Target at $44.60 - Defense World

May 20, 2025
pulisher
May 19, 2025

Bluebird Beats Patent Case Over Blood Disease Therapies - Law360

May 19, 2025
pulisher
May 19, 2025

Bluebird Wins Patent Fight Over Two High-Priced Gene Therapies - Bloomberg Law News

May 19, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

May 18, 2025

Bluebird Bio Inc (BLUE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
大文字化:     |  ボリューム (24 時間):